3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
2
Thoracic
1
Other hematologic neoplasm
1
Myeloid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Thromboembolism
3
Venous Thrombosis
2
Colorectal Neoplasms
2
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Pulmonary Embolism
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Hemorrhage
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
6
Nivolumab
5
Magnetic Resonance Spectroscopy
4
fludarabine
3
Sirolimus
3
Radiotherapy
3
Methods
3
Gemcitabine
3
Early Intervention, Educational
3
Drug Therapy
3
Biopsy
3
spartalizumab
2
epacadostat
2
atezolizumab
2
X-Rays
2
Topotecan
2
Surveys and Questionnaires
2
Specimen Handling
2
Palliative Care
2
Nuclear Medicine Department, Hospital
2
Ipilimumab
2
Interleukin-2
2
Educational Status
2
Dasatinib
2
Cyclophosphamide
2
Carboplatin
2
vocimagene amiretrorepvec
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Tinzaparin
×
Gastrointestinal
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled